{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:34Z","timestamp":1793286214172,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.gore.2024.101453","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:28:33Z","timestamp":1720114113000},"page":"101453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pembrolizumab-induced myasthenia gravis: Two patients\u2019 experiences"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-3623","authenticated-orcid":false,"given":"Leslie","family":"Montag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Piver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Vidalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunja","family":"Rungruang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2024.101453_b0005","unstructured":"Bird, S.J., Levine, J.M., 2024. Myasthenia Crisis. In J.M. Schefner, P.E. Parsons, & A.A. Rubinstein (Eds.), UpToDate. Available from: https:\/\/www.uptodate.com\/contents\/myasthenic-crisis?search=myasthenia%20gravis%20crisis&source=search_result&selectedTitle=1%7E83&usage_type=default&display_rank=1#H1075786823."},{"key":"10.1016\/j.gore.2024.101453_b0010","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect It so You Can Treat It: A Case Series and Proposed Checklist to Detect Neurotoxicity in Checkpoint Therapy","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalSci."},{"key":"10.1016\/j.gore.2024.101453_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Regional Health \u2013 Western Pacific"},{"issue":"6","key":"10.1016\/j.gore.2024.101453_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CJI.0000000000000422","article-title":"Pembrolizumab-induced Myasthenia Gravis: Literature review of ocular manifestations and a refractory case","volume":"45","author":"Dugena","year":"2022","journal-title":"J. Immunother."},{"key":"10.1016\/j.gore.2024.101453_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong","year":"2021","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.gore.2024.101453_b0030","unstructured":"Flynn, J.P., Gerriets, V., 2023. Pembrolizumab. StatPearls [Internet]. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546616\/."},{"issue":"6","key":"10.1016\/j.gore.2024.101453_b0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.anai.2021.03.003","article-title":"Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy","volume":"126","author":"Goleva","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"3","key":"10.1016\/j.gore.2024.101453_b0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: New case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.gore.2024.101453_b0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gore.2024.101453_b0050","unstructured":"Myasthenia Gravis Foundation of America, 2023. MGFA Clinical Classification. https:\/\/myasthenia.org\/Portals\/0\/MGFA%20Classification.pdf. Accessed on July 28, 2023."},{"key":"10.1016\/j.gore.2024.101453_b0055","unstructured":"National Comprehensive Cancer Network, 2023. Management of Immune Checkpoint Inhibitor-Related Toxicities (version 1.2024). ICI_NEURO-1. Accessed April 19, 2024."},{"issue":"1","key":"10.1016\/j.gore.2024.101453_b0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2024.101453_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.gore.2024.101453_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.03.006","article-title":"Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis","volume":"113","author":"Tedbirt","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.gore.2024.101453_b0075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/imt-2019-0106","article-title":"Myasthenia gravis induced by avelumab","volume":"11","author":"Yuen","year":"2019","journal-title":"Immunotherapy"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924001322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924001322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:35:15Z","timestamp":1722238515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":15,"alternative-id":["S2352578924001322"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101453","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced myasthenia gravis: Two patients\u2019 experiences","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101453"}}